Zenas BioPharma (ZBIO) Total Non-Current Liabilities (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Total Non-Current Liabilities of $350.7 million for Q1 2026, up 344.78% quarter-over-quarter from $78.8 million in Q4 2025.
Zenas BioPharma (ZBIO) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Zenas BioPharma's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $350.7 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $350.7 million; the TTM figure through Mar 2026 stood at $350.7 million (changed N/A YoY), while the FY2025 annual figure was $78.8 million, up 36068.35% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $350.7 million, up from $78.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $350.7 million in Q1 2026, with the low at $218000.0 in Q4 2024.
- The 4-year median for Total Non-Current Liabilities is $73.2 million (2025), against an average of $105.3 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities tumbled 99.07% in 2024, then soared 36068.35% in 2025.
- Zenas BioPharma's Total Non-Current Liabilities stood at $23.5 million in 2023, then sank by 99.07% to $218000.0 in 2024, then jumped by 36068.35% to $78.8 million in 2025, then surged by 344.78% to $350.7 million in 2026.
- Business Quant data shows ZBIO's Total Non-Current Liabilities at $350.7 million in Q1 2026, $78.8 million in Q4 2025, and $73.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | 388.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 388.78 Mn |
| Mar 31, 2026 | 350.69 Mn |
| Dec 31, 2025 | 78.85 Mn |
| Sep 30, 2025 | 73.17 Mn |
| Dec 31, 2024 | 218,000.00 |
| Dec 31, 2023 | 23.52 Mn |